Table 2.

Measures at Each Time Point^a and Covariates to be Examined as Predictors of Outcomes

	Eligibility	Baseline Week 0	Week 1	Week 4	Week 8	Week 10	Week 12	Week 26
Smoking Abstinence Outcomes
Anatabine/anabasine (primary)							x
Cotinine (secondary)								x
Patient- and Provider-Centered Outcomes
Reduction in nicotine exposure (cotinine)		x						x
Reduction in carcinogen exposure (NNAL)		x					x
Days abstinent				x	x		x	x
Treatment-related side effects		x		x	x		x
Demographics
Demographics (e.g., age, gender, education, income)	x	x
Perceived health		x
Body mass index		x
Smoking and Tobacco Use History
Past 30 day use of all tobacco products		x		x	x		x	x
Menthol/Non-Menthol		x
Age first used cigarettes		x
Identity as smoker		x
Reasons for non-daily smoking		x
Non-daily type (i.e., native, converted)		x
Triggers for smoking		x
Social smoking		x
Withdrawal (Minnesota Withdrawal Questionnaire)		x		x
Craving (Questionnaire of Brief Smoking Urges)		x		x
Nicotine dependence (Time to First Cigarette)		x
Dependence motives (Wisconsin Inventory of Smoking Dependence Motives)		x
Social Influences on Smoking
Smoking status of partner/spouse		x
Number of smokers in household		x
Home smoking restrictions		x
Number of friends/family who smoke		x
Quitting History
Past year quitting (# of times and longest period)		x
Use of pharmacological and behavioral aids to quit	x
Alcohol, Other Drugs, and Depressive Symptoms
Depressive symptoms (Patient Health Questionnaire-2)		x
Alcohol use (AUDIT-C)		x		x	x		x	x
Marijuana use		x		x	x		x	x
Use of prescription pain relievers		x
Treatment Process
Counseling completion		x	x	x	x	x
NRT use (C+NRT only)				x	x		x	x

^aAssessments were completed in-person at Weeks 0, 4, 8, 12, and 26 and by phone at Weeks 1 and10.